News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
26,270 Results
Type
Article (999)
Company Profile (2)
Press Release (25269)
Section
Business (12694)
Career Advice (68)
Deals (1577)
Drug Development (2200)
Employer Resources (3)
FDA (392)
Job Trends (633)
News (15959)
Policy (700)
Tag
Academia (25)
Allergies (2)
Alliances (653)
ALS (2)
Alzheimer's disease (17)
Antibody-drug conjugate (ADC) (12)
Approvals (416)
Artificial intelligence (5)
Autoimmune disease (1)
Automation (3)
Bankruptcy (12)
Best Places to Work (591)
Biosimilars (8)
Biotechnology (1)
Bladder cancer (8)
Brain cancer (1)
Breast cancer (13)
Cancer (136)
Cardiovascular disease (30)
Career advice (64)
CAR-T (4)
Cell therapy (15)
Cervical cancer (3)
Clinical research (2059)
Collaboration (18)
Compensation (44)
COVID-19 (70)
CRISPR (1)
C-suite (6)
Cystic fibrosis (3)
Data (217)
Depression (6)
Diabetes (22)
Diagnostics (283)
Digital health (1)
Drug discovery (4)
Drug pricing (1)
Duchenne muscular dystrophy (5)
Earnings (12795)
Editorial (1)
Employer branding (1)
Employer resources (2)
Events (1520)
Executive appointments (2)
FDA (611)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (4)
Funding (21)
Gene editing (3)
Generative AI (1)
Gene therapy (7)
GLP-1 (50)
Government (81)
Guidances (144)
Healthcare (609)
HIV (2)
IgA nephropathy (6)
Immunology and inflammation (8)
Immuno-oncology (1)
Indications (3)
Infectious disease (75)
Inflammatory bowel disease (4)
Intellectual property (6)
Interviews (13)
IPO (1253)
IRA (1)
Job creations (87)
Job search strategy (52)
JPM (1)
Labor market (2)
Layoffs (13)
Legal (127)
Liver cancer (1)
Lung cancer (16)
Lymphoma (17)
Management (1)
Manufacturing (7)
MASH (9)
Medical device (653)
Medtech (656)
Mergers & acquisitions (325)
Metabolic disorders (54)
Multiple sclerosis (4)
NASH (2)
Neurodegenerative disease (5)
Neuropsychiatric disorders (3)
Neuroscience (50)
NextGen: Class of 2026 (129)
Non-profit (69)
Now hiring (1)
Obesity (21)
Opinion (2)
Ovarian cancer (5)
Pain (1)
Pancreatic cancer (7)
Parkinson's disease (5)
Partnered (1)
Patents (7)
Patient recruitment (9)
Peanut (2)
People (484)
Pharmaceutical (1)
Phase 1 (441)
Phase 2 (817)
Phase 3 (896)
Pipeline (590)
Policy (4)
Postmarket research (115)
Preclinical (149)
Press Release (1)
Prostate cancer (5)
Radiopharmaceuticals (5)
Rare diseases (14)
Real estate (86)
Recruiting (1)
Regulatory (587)
Reports (3)
Research institute (20)
Resumes & cover letters (5)
RSV (3)
Schizophrenia (5)
Series A (1)
Series B (4)
Service/supplier (1)
Sickle cell disease (1)
Spinal muscular atrophy (5)
Startups (48)
Stomach cancer (1)
Vaccines (36)
Venture capital (3)
Weight loss (11)
Women's health (4)
Date
Last 7 days (22)
Last 30 days (53)
Last 365 days (1552)
2026 (64)
2025 (1580)
2024 (1744)
2023 (2008)
2022 (2101)
2021 (2099)
2020 (1688)
2019 (1261)
2018 (1025)
2017 (691)
2016 (435)
2015 (613)
2014 (421)
2013 (270)
2012 (314)
2011 (387)
2010 (425)
Location
Africa (21)
Alabama (4)
Arizona (7)
Asia (1422)
Australia (131)
California (501)
Canada (144)
China (40)
Colorado (29)
Connecticut (44)
Delaware (18)
Europe (3137)
Florida (100)
Georgia (17)
Idaho (2)
Illinois (38)
India (6)
Indiana (31)
Japan (9)
Kansas (6)
Kentucky (3)
Louisiana (4)
Maine (5)
Maryland (61)
Massachusetts (367)
Michigan (22)
Minnesota (28)
Missouri (6)
Montana (3)
Nevada (7)
New Hampshire (6)
New Jersey (217)
New York (129)
North Carolina (73)
Northern California (261)
Ohio (9)
Pennsylvania (137)
Puerto Rico (1)
South America (33)
Southern California (200)
Tennessee (5)
Texas (69)
United States (1975)
Utah (21)
Virginia (7)
Washington State (33)
Wisconsin (6)
26,270 Results for "116".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nanotechnology Market Size Expected to Hit USD 116.39 Billion by 2034
August 29, 2025
·
1 min read
Press Releases
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
September 26, 2025
·
4 min read
Press Releases
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
September 30, 2025
·
8 min read
Press Releases
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
September 4, 2025
·
5 min read
Press Releases
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
June 12, 2025
·
7 min read
Press Releases
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
May 5, 2025
·
33 min read
Press Releases
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
October 20, 2025
·
5 min read
Job Trends
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Barcelona, Spain.
April 29, 2024
·
12 min read
Press Releases
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
December 2, 2024
·
7 min read
Press Releases
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
November 25, 2024
·
1 min read
1 of 2,627
Next
